Hypoparathyroidism secondary prevention

Jump to navigation Jump to search

Hypoparathyroidism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypoparathyroidism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypoparathyroidism secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hypoparathyroidism secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypoparathyroidism secondary prevention

CDC on Hypoparathyroidism secondary prevention

Hypoparathyroidism secondary prevention in the news

Blogs on Hypoparathyroidism secondary prevention

Directions to Hospitals Treating Hypoparathyroidism

Risk calculators and risk factors for Hypoparathyroidism secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Omodamola Aje B.Sc, M.D. [2]

Overview

There are no established measures for the secondary prevention of [disease name].

OR

Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].

Secondary Prevention

  • Effective measures for the secondary prevention of hypoparathyroidism is monitoring patients on conventional tharapy. Monitoring guidelines on conventional therapy include:[1][2]
    • Serum calcium (corrected for albumin), phosphorus, and creatinine concentrations should be measured weekly to monthly during dose adjustments, and twice annually once a stable regimen has been reached.
    • 24 hour Urinary calcium and urine creatinine should be considered during dose adjustments and should be measured twice annually on a stable regimen to evaluate for renal toxicity.
    • Estimated gomerular filtration rate (eGFR) should be monitored yearly or more frequently if the clinical situation is appropriate.
  • Other imaging studies and examinations may be done as clinically indicated.
    • Renal imaging may be done to rule out nephrolithiasis/nephrocalcinosis.
    • Ophthalmological exam may be done to rule out cataracts.
    • Central nervous system imaging may be done to rule out basal ganglia and other sites of calcification.
    • Bone mineral density may be done to rule out to rule out skeletal abnormalities.

References

  1. Brandi ML, Bilezikian JP, Shoback D, Bouillon R, Clarke BL, Thakker RV, Khan AA, Potts JT (2016). "Management of Hypoparathyroidism: Summary Statement and Guidelines". J. Clin. Endocrinol. Metab. 101 (6): 2273–83. doi:10.1210/jc.2015-3907. PMID 26943719.
  2. Bilezikian JP, Brandi ML, Cusano NE, Mannstadt M, Rejnmark L, Rizzoli R, Rubin MR, Winer KK, Liberman UA, Potts JT (2016). "Management of Hypoparathyroidism: Present and Future". J. Clin. Endocrinol. Metab. 101 (6): 2313–24. doi:10.1210/jc.2015-3910. PMC 5393596. PMID 26938200.

Template:WH Template:WS